Slingshot members are tracking this event:
AbbVie commences Phase 3 trial of ABT-494 for rheumatoid arthritis, expected completion mid-2017
Do you think this event is important to the companies below? How will it affect their stock price?
|Impact on Stocks
Slingshot Insights Explained
Jun 07, 2017
Don’t see a project related to the catalyst you care about?
Related Keywords Phase 3 Study, Abt-494, Rheumatoid Arthritis